一次抗体と二次抗体-抗-エピトープタグ、免疫測定、Cas 9 » Primary Antibodies » Immune Checkpoint Antibodies » Human PD-L1 Antibody (PDL1.D1), mAb, Mouse
Human PD-L1 Antibody (PDL1.D1), MAb, Mouse

ELISA binding of human PD-L1 antibody PDL1.D1 (GenScript, A01830) with Human PD-L1 recombinant protein (Z03371, PD L1 Fc Chimera, Human).
Coating antigen: PD-L1-Fc, 1µg/ml.
PD-L1 antibody dilution start from 1000ng/ml, EC50= 4.4 ng/ml

Human PD-L1 Antibody (PDL1.D1), MAb, Mouse

ELISA blocking of human PD-L1 antibody PDL1.D1 (GenScript, A01830) against Human PD-1 recombinant protein (Z03370, PD 1 Fc Chimera, Human) binding with Human PD-L1 recombinant protein (Z03371, PD L1 Fc Chimera, Human).
Coating antigen: PD-L1-Fc, 1µg/ml.
PD-1-Fc final concentration: 0.5µg /ml
PD-L1 antibody dilution start from 50µg/ml, IC50= 0.5µg/ml

Human PD-L1 Antibody (PDL1.D1), MAb, Mouse

Flow cytometric analysis of CHO-K1/PD-L1 stable cell expressing PD-L1 (GenScript, M00543, Red) and CHO negative control cell (Black) with Human PD-L1 Antibody PDL1.D1, (GenScript, A01830)
Antibody working concentration: 5 µg/ml, 2.5x105 cells/reaction
The signal was developed with iFluor647 conjugated Goat Anti-Mouse IgG

Human PD-L1 Antibody (PDL1.D1), MAb, Mouse

FACS ligand blocking test of Human PD-L1 Antibody PDL1.D1 (GenScript, A01830) block the binding of human PD-L1 cell line (GenScript, M00543) with Human PD-1(Z03370, PD 1 Fc Chimera, Human, Red) and CHO negative control cell (Black)
Antibody working concentration: 5 µg/ml, 2.5x105 cells/reaction
Ligand (PD-1) working concentration: 1 μg/ml
The signal was developed with Alexa Fluor 647 Conjugated Affinipure Goat anti-human IgG (H + L).

Human PD-L1 Antibody (PDL1.D1), mAb, Mouse

The product is specific for human PD-L1 (UniProt Accession: Q9NZQZ). This antibody blocks human PD-1 binding with human PD-L1 expression cell line in flow cytometry assay.
A01830
¥19,506.00

Ask us a question
Overview
Specificity The product is specific for human PD-L1 (UniProt Accession: Q9NZQZ). This antibody blocks human PD-1 binding with human PD-L1 expression cell line in flow cytometry assay.
Host Species Mouse
Immunogen Recombinant human PD-L1-Fc (Z03371)
Conjugate Unconjugated

Applications
Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.
Application Recommended Usage
ELISA  0.01-0.1 µg/ml
Competitive ELISA 10-50 µg/ml
Flow Cytometry  2-10 µg/ml
Flow cytometry  2-10 µg/ml

Properties
Form Lyophilized
Storage Buffer lyophilized with PBS, pH 7.4, containing 0.02% sodium azide.
Reconstitution Reconstitute the lyophilized powder with deionized water (or equivalent) to an final concentration of 0.5 mg/mL.
Storage Instructions The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid repeated freezing and thawing cycles.
Purification Protein A affinity column
Isotype Mouse IgG1,κ
Clonality Monoclonal
Clone ID PDL1.D1
Note GenScript can customize this product per customer's request including product size, buffer components, etc.

Examples
  • Human PD-L1 Antibody (PDL1.D1), MAb, Mouse
    • Human PD-L1 Antibody (PDL1.D1), MAb, Mouse

    ELISA binding of human PD-L1 antibody PDL1.D1 (GenScript, A01830) with Human PD-L1 recombinant protein (Z03371, PD L1 Fc Chimera, Human).
    Coating antigen: PD-L1-Fc, 1µg/ml.
    PD-L1 antibody dilution start from 1000ng/ml, EC50= 4.4 ng/ml

  • Human PD-L1 Antibody (PDL1.D1), MAb, Mouse
    • Human PD-L1 Antibody (PDL1.D1), MAb, Mouse

    ELISA blocking of human PD-L1 antibody PDL1.D1 (GenScript, A01830) against Human PD-1 recombinant protein (Z03370, PD 1 Fc Chimera, Human) binding with Human PD-L1 recombinant protein (Z03371, PD L1 Fc Chimera, Human).
    Coating antigen: PD-L1-Fc, 1µg/ml.
    PD-1-Fc final concentration: 0.5µg /ml
    PD-L1 antibody dilution start from 50µg/ml, IC50= 0.5µg/ml

  • Human PD-L1 Antibody (PDL1.D1), MAb, Mouse
    • Human PD-L1 Antibody (PDL1.D1), MAb, Mouse

    Flow cytometric analysis of CHO-K1/PD-L1 stable cell expressing PD-L1 (GenScript, M00543, Red) and CHO negative control cell (Black) with Human PD-L1 Antibody PDL1.D1, (GenScript, A01830)
    Antibody working concentration: 5 µg/ml, 2.5x105 cells/reaction
    The signal was developed with iFluor647 conjugated Goat Anti-Mouse IgG

  • Human PD-L1 Antibody (PDL1.D1), MAb, Mouse
    • Human PD-L1 Antibody (PDL1.D1), MAb, Mouse

    FACS ligand blocking test of Human PD-L1 Antibody PDL1.D1 (GenScript, A01830) block the binding of human PD-L1 cell line (GenScript, M00543) with Human PD-1(Z03370, PD 1 Fc Chimera, Human, Red) and CHO negative control cell (Black)
    Antibody working concentration: 5 µg/ml, 2.5x105 cells/reaction
    Ligand (PD-1) working concentration: 1 μg/ml
    The signal was developed with Alexa Fluor 647 Conjugated Affinipure Goat anti-human IgG (H + L).


Background
Target Background Programmed cell death 1 ligand 1 is one of the two ligands of PD-1. PD-L1 is expressed on macrophages, T cells, B cells, NK cells, DCs and some cancer cell surface. Binding of PD-1 with PD-L1 could result in down-regulation of the immune system by inhibiting the T-cell activation process. Thus, PD-L1 is an important immune checkpoint and popular target for therapeutic antibodies against many cancers.GenScript Human PD-L1 Antibody (PDL1.D1), mAb, Mouse is produced from the hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from mouse immunized with recombinant human PD-L1-Fc(Z03371).
Synonyms Mouse monoclonal to Programmed Death Ligand 1/ B7-H/ B7H1/ PDL1/ CD274 / PDCD1L1/ PDCD1LG1

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.